Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Galcanezumab for Preventing Episodic Migraine in Children and Teens Aged 6 to 17

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying episodic migraine in children and teenagers aged 6 to 17 years. The treatment being tested is called Galcanezumab, which is a solution for injection. It is also known by its code name, LY2951742. The study aims to evaluate how effective and safe Galcanezumab is in preventing migraine headaches in young participants.

Participants in the study will receive either Galcanezumab or a placebo over a period of three months. The study is designed to compare the effects of Galcanezumab with the placebo to see if it can reduce the number of days participants experience migraine headaches each month. The study is conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, which is known as a double-blind study.

The main goal is to determine if Galcanezumab is better than the placebo in decreasing the frequency of migraine headaches. This study is part of ongoing research to find effective treatments for managing migraines in young people, aiming to improve their quality of life by reducing the burden of migraine attacks.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant is confirmed to have a diagnosis of migraine with or without aura, as defined by the International Headache Society guidelines.

    The participant must have a history of migraine headaches for at least 6 months prior to the screening.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to establish a baseline for the number of monthly migraine headache days.

    This baseline will be used to measure changes throughout the study.

  3. Step 3

    Treatment period

    The treatment period lasts for 3 months and is double-blind, meaning neither the participant nor the researchers know who receives the actual medication or the placebo.

    Participants receive either galcanezumab or a placebo. Both are administered as a solution for injection.

    The primary goal is to evaluate the effectiveness and safety of galcanezumab in reducing the number of monthly migraine headache days.

  4. Step 4

    Follow-up assessments

    Throughout the treatment period, regular follow-up assessments are conducted to monitor the participant's response to the treatment.

    These assessments help determine any changes in the frequency of migraine headache days.

  5. Step 5

    End of study evaluation

    At the end of the 3-month treatment period, a final evaluation is conducted.

    The primary endpoint is the change from baseline in the number of monthly migraine headache days.

Who can join the trial?

5 criteria

  • The patient must be between 6 and 17 years old.
  • The patient can be either male or female.
  • The patient must have a diagnosis of migraine. A migraine is a type of headache that can cause severe pain, often accompanied by nausea and sensitivity to light and sound.
  • The patient may have migraines with or without aura. An aura is a visual or sensory disturbance that some people experience before a migraine, like seeing flashing lights or feeling tingling.
  • The patient must have had a history of migraine headaches for at least 6 months before the screening for the study.

Who cannot join the trial?

9 criteria

  • Participants who are not between the ages of 6 to 17 years old.
  • Participants who do not have episodic migraine. This means they do not experience migraine headaches that occur on some days but not every day.
  • Participants who have any other medical condition that might interfere with the study or make it unsafe for them to participate.
  • Participants who are currently taking other medications that could affect the study results.
  • Participants who have had a recent change in their migraine treatment plan.
  • Participants who are unable to follow the study procedures or attend the required visits.
  • Participants who have a history of not following medical advice or treatment plans.
  • Participants who are pregnant or breastfeeding.
  • Participants who have participated in another clinical trial recently.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Galcanezumab is a medication being studied for its ability to prevent migraines in children and teenagers aged 6 to 17. It is designed to reduce the number of days each month that a person experiences migraine headaches. The study aims to determine if galcanezumab is more effective than a placebo in achieving this goal over a three-month period.

What is already known about the treatment

Galcanezumab – This medication is administered via injection and is currently being studied for its effectiveness in preventing episodic migraines in children and adolescents aged 6 to 17. It is in the clinical trial phase, with ongoing research to establish its safety and efficacy. Galcanezumab is primarily indicated for the prevention of migraine headaches. It works by targeting and blocking the activity of a protein called calcitonin gene-related peptide (CGRP), which is involved in the transmission of pain and the development of migraines. It is classified as a monoclonal antibody used in the treatment of migraines.

Investigated diseases

Migraine – Migraine is a neurological condition characterized by intense, throbbing headaches, often accompanied by nausea, vomiting, and sensitivity to light and sound. These headaches typically occur on one side of the head and can last from a few hours to several days. Migraine attacks may be preceded by warning symptoms known as aura, which can include visual disturbances or tingling sensations. The frequency and severity of migraines can vary widely among individuals, with some experiencing chronic episodes. Factors such as stress, hormonal changes, certain foods, and environmental triggers can contribute to the onset of a migraine. Over time, migraines can significantly impact daily activities and quality of life.
Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase IIITrial ID2023-505836-36-00Protocol codeI5Q-MC-CGASEstimated enrolment300 patientsSponsorEli Lilly & Co.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).